PAVmed Inc. (PAVM)

1.7600 +0.0200 (+1.15%) As of 09:41AM EDT. Market open.

PAVmed Inc.

360 Madison Avenue
25th Floor
New York, NY 10017
United States
917-813-1828
https://www.pavmed.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 107

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Lishan Aklog M.D.	Chairman & CEO	945.09k	N/A	1966
Mr. Dennis M. McGrath CPA	President, CFO & Corporate Secretary	663.38k	N/A	1957
Mr. Shaun M. O'Neill M.B.A.	Executive VP & COO	447.47k	N/A	1983
Dr. Brian J. deGuzman M.D.	Executive VP, Chief Technology & Compliance Officer	427.6k	N/A	1965
Dr. Suman M. Verma M.D., Ph.D.	Senior VP of Molecular Genetics & Chief Scientific Officer	N/A	N/A	N/A
Michael Parks	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Michael Adam Gordon	Executive VP, General Counsel & Secretary	N/A	N/A	1974
Dr. Deepika A. Lakhani Ph.D.	Senior VP, Chief Regulatory & Quality Officer	N/A	N/A	N/A
Dr. Victoria T. Lee M.D.	Senior VP & Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Corporate governance

PAVmed Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.